Author Archives: Marta Figueiredo PhD

Ruzurgi Available in Canada After Brief Interruption

Health Canada has re-issued its approval of Ruzurgi (amifampridine) for the treatment of Lambert-Eaton myasthenic syndrome (LEMS) in patients 6 and older. The decision comes two months after the Federal Court in Canada cancelled the therapy’s approval in the country due to data protection-related issues filed by Catalyst Pharmaceuticals, which commercializes…

Plasma Exchange May Treat Lung Cancer-linked LEMS and PCD

Plasmapheresis, or plasma exchange, may be an effective way of managing small cell lung cancer-associated Lambert-Eaton myasthenic syndrome (LEMS) and paraneoplastic cerebellar degeneration (PCD), combined with peripheral nerve damage, a case report suggests. The simultaneous development of LEMS and PCD is usually associated with small cell lung cancer (SCLC)…

LEMS-associated Respiratory Problems May Lead to Heart Dysfunction, Case Report Shows

Lambert‐Eaton myasthenic syndrome-associated diaphragm weakness and subsequent respiratory problems may impair heart function, a case study shows. The report, “Lambert Eaton Myasthenic Syndrome Presenting as Hypoventilation-Induced Right Heart Dysfunction,” was accepted for presentation at the American Thoracic Society (ATS) 2020 International Conference, which was planned…